Activity of Combination Chemotherapy, Docetaxel and Epirubicin as Neoadjuvant Therapy for Women with Breast Cancer

Background: This study assesses the efficacy of epirubicin and docetaxel as neoadjuvant therapy for women with breast cancer. Patients and Methods: This is a single institution, single arm, phase II study of epirubicin given at 75 mg/m 2 and docetaxel at 75 mg/m 2 every three weeks for four cycles p...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-11, Vol.26 (6C), p.4911-4916
Main Authors: TFAYLI, Arafat, HOLTER, Jennifer, BOVA, Abby, VENKATAPPA, Siddhartha, BULLOCK, Susie, DOOLEY, William, OZER, Howard
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - surgery
Disease-Free Survival
Epirubicin - administration & dosage
Epirubicin - adverse effects
Female
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Neoadjuvant Therapy
Taxoids - administration & dosage
Taxoids - adverse effects
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: This study assesses the efficacy of epirubicin and docetaxel as neoadjuvant therapy for women with breast cancer. Patients and Methods: This is a single institution, single arm, phase II study of epirubicin given at 75 mg/m 2 and docetaxel at 75 mg/m 2 every three weeks for four cycles prior to surgical excision in women with large breast cancers. Pegfilgrastim was routinely administered as primary prophylaxis against febrile neutropenia. Results: Out of the 18 patients enrolled on the study, 12 (66.7%) had a clinical response and 13 (72.2%) had a pathologic response, with a pathologic complete response of 5.6%. Pre-menopausal women and patients with estrogen receptor positive tumors had a higher response rate. One patient died due to sepsis and febrile neutropenia. Conclusion: Combination chemotherapy with epirubicin and docetaxel is highly active against breast cancer. With close monitoring for toxicity, this combination can be safely administered with mild side-effects.
ISSN:0250-7005
1791-7530